

8/21/24 MarketLine Fin. Deals Tracker 00:00:00

MarketLine Financial Deals Tracker  
Copyright (c) 2001-2016 Marketline.

August 21, 2024

Oragenics Files Prospectus to Raise Approximately USD4.9 Million in Public Offering of shares

Oragenics Inc, a US-based company which carries out research and development (R&D) to develop new treatments for oral mucositis in cancer patients, obesity, tooth decays and healthcare-associated infections, has filed prospectus to raise USD4.9 million in public offering of shares. The company will issue up to 2,403,846 shares at an assumed public offering price of USD2.08 per share. Dawson James Securities Inc, acting as placement agent for the offering. ArentFox Schiff LLP, **Shumaker, Loop** & Kendrick, LLP are acting as legal advisors for the offering.

Oragenics, Inc. intends to use the net proceeds from this offering, along with its existing cash and cash equivalents, to fund its ongoing ONP-2 concussion clinical trials, along with other related research and development activities, as well as for working capital and other general corporate purposes.

**Deal In Brief**

Deal Value (US\$ Million)	4.9
Deal Type	IPO
Sub-Category	Secondary Offering,Filing
Deal Status	Announced: 2024-08-16

**Deal Participants**

Target (Company)	Oragenics Inc
------------------	---------------

**Deal Rationale**

Offer Price (\$ per share)	2.08
No. Shares Issued	2403846

---- **Index References** ----

Company: DAWSON JAMES SECURITIES, INC.; ORAGENICS, INC.; **SHUMAKER, LOOP** & KENDRICK, LLP

News Subject: (Business Management (1BU42); Corporate Events (1CR05); Corporate Funding (1XO17); Equity Instruments (1EQ90); Funding Instruments (1FU41); Joint Ventures (1JO05); Secondary Stock Offerings (1SE74); Stock Markets (1ST45); Stock Offerings (1ST44))

Industry: (Financial Services (1FI37); Investment Management (1IN34); Securities Investment (1SE57))

Language: EN

Other Indexing: (Dawson James Securities Inc; Oragenics Inc; **Shumaker, Loop** & Kendrick, LLP)

Word Count: 166

---

End of Document

© 2024 Thomson Reuters. No claim to original U.S. Government Works.

**NewsRoom**